Overview

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Status:
Completed

Trial end date:
2020-12-19

Target enrollment:

Participant gender:

Summary

In this open label, single-sequence study, subjects received one dose of XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation at the start of study on Day 1 and Day 6. Omeprazole 40 mg was administered on Day 2, 3, 4, 5 and 6. The study was conducted in two groups.

Phase:

Phase 1

Details

Lead Sponsor:

Xspray Pharma AB

Collaborator:

Axis Clinicals Limited

Treatments:

Dasatinib
Omeprazole